A woman with post-traumatic stress disorder participated in an MDMA study hoping for relief, but instead experienced intense despair when her symptoms did not improve. She even considered suicide at one point. Despite her struggles, she resisted jumping in front of a train out of fear that it would impact the success of the MDMA research. Suicidal ideation should be considered an adverse event in clinical trials, but this incident was not reflected in the published data. The participant’s story highlights the complexities and challenges of using psychedelic therapy for treating mental health disorders.
Source link
MDMA treatment for PTSD questioned before key FDA hearing
